Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - ADMA Biologics

Drug Profile

Immune globulin - ADMA Biologics

Alternative Names: ASCENIV; IGIV - ADMA Biologics; Immune globulin intravenous human - ADMA Biologics; Immune globulin intravenous, human – slra; Respiratory syncytial virus immune globulin - ADMA Biologics; RI-001; RI-002

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADMA Biologics; Baylor College of Medicine
  • Developer ADMA Biologics
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immunodeficiency disorders
  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 21 Oct 2019 Launched for Immunodeficiency disorders (In adolescents, In children) in USA (IV) - First Global Launch
  • 17 Oct 2019 ADMA Biologics announces intention to launch to RI 002 for Immunodeficiency disorders in the fourth quarter of 2019
  • 08 Oct 2019 Clinical trials in Respiratory syncytial virus infections (In children) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top